An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. tuberculosis specific antibodies in Cape Town, South Africa
Background: Mycobacterium tuberculosis (Mtb) infection is inferred from positive results of T-cell immune conversion assays measuring Mtb-specific interferon gamma production or tuberculin skin test (TST) reactivity. Certain exposed individuals do not display T-cell immune conversion in these assays and do not develop TB. Here we report a hitherto unknown form of this phenotype: HIV-1-positive persistently TB, tuberculin and IGRA negative (HITTIN). Methods: A community-based case-control design was used to systematically screen and identify adults living with HIV (HIV+), aged 35–60 years, who met stringent study criteria, and then longitudinally followed up for repeat IGRA and TST testing. Participants had no history of TB despite living in TB hyper-endemic environments in Cape Town, South Africa with a provincial incidence of 681/100,000. Mtb-specific antibodies were measured using ELISA and Luminex. Findings: We identified 48/286 (17%) individuals who tested persistently negative for Mtb-specific T-cell immunoreactivity (three negative Quantiferon results and one TST = 0mm) over 206±154 days on average. Of these, 97·2% had documented CD4 counts<200 prior to antiretroviral therapy (ART). They had received ART for 7·0±3·0 years with a latest CD4 count of 505·8±191·4 cells/mm3. All HITTIN sent for further antibody testing (n=38) displayed Mtb-specific antibody titres. Interpretation: Immune reconstituted HIV+ persons can be persistently non-immunoreactive to TST and interferon-γ T-cell responses to Mtb, yet develop species-specific antibody responses. Exposure is evidenced by Mtb-specific antibody titres. Our identification of HIV+ individuals displaying a persisting lack of response to TST and IGRA T-cell immune conversion paves the way for future studies to investigate this phenotype in the context of HIV-infection that so far have received only scant attention..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
---|---|
Enthalten in: |
EBioMedicine - 61(2020), Seite 103053- |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Elouise E. Kroon [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Antibodies |
---|
doi: |
10.1016/j.ebiom.2020.103053 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ053125339 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ053125339 | ||
003 | DE-627 | ||
005 | 20230503144210.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ebiom.2020.103053 |2 doi | |
035 | |a (DE-627)DOAJ053125339 | ||
035 | |a (DE-599)DOAJ778da5d84cb64b9698dfc80977800634 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a R5-920 | |
100 | 0 | |a Elouise E. Kroon |e verfasserin |4 aut | |
245 | 1 | 3 | |a An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. tuberculosis specific antibodies in Cape Town, South Africa |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: Mycobacterium tuberculosis (Mtb) infection is inferred from positive results of T-cell immune conversion assays measuring Mtb-specific interferon gamma production or tuberculin skin test (TST) reactivity. Certain exposed individuals do not display T-cell immune conversion in these assays and do not develop TB. Here we report a hitherto unknown form of this phenotype: HIV-1-positive persistently TB, tuberculin and IGRA negative (HITTIN). Methods: A community-based case-control design was used to systematically screen and identify adults living with HIV (HIV+), aged 35–60 years, who met stringent study criteria, and then longitudinally followed up for repeat IGRA and TST testing. Participants had no history of TB despite living in TB hyper-endemic environments in Cape Town, South Africa with a provincial incidence of 681/100,000. Mtb-specific antibodies were measured using ELISA and Luminex. Findings: We identified 48/286 (17%) individuals who tested persistently negative for Mtb-specific T-cell immunoreactivity (three negative Quantiferon results and one TST = 0mm) over 206±154 days on average. Of these, 97·2% had documented CD4 counts<200 prior to antiretroviral therapy (ART). They had received ART for 7·0±3·0 years with a latest CD4 count of 505·8±191·4 cells/mm3. All HITTIN sent for further antibody testing (n=38) displayed Mtb-specific antibody titres. Interpretation: Immune reconstituted HIV+ persons can be persistently non-immunoreactive to TST and interferon-γ T-cell responses to Mtb, yet develop species-specific antibody responses. Exposure is evidenced by Mtb-specific antibody titres. Our identification of HIV+ individuals displaying a persisting lack of response to TST and IGRA T-cell immune conversion paves the way for future studies to investigate this phenotype in the context of HIV-infection that so far have received only scant attention. | ||
650 | 4 | |a Resister | |
650 | 4 | |a Early clearance | |
650 | 4 | |a Interferon gamma release assay | |
650 | 4 | |a Tuberculin skin test | |
650 | 4 | |a Antibodies | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
653 | 0 | |a Medicine (General) | |
700 | 0 | |a Craig J. Kinnear |e verfasserin |4 aut | |
700 | 0 | |a Marianna Orlova |e verfasserin |4 aut | |
700 | 0 | |a Stephanie Fischinger |e verfasserin |4 aut | |
700 | 0 | |a Sally Shin |e verfasserin |4 aut | |
700 | 0 | |a Sihaam Boolay |e verfasserin |4 aut | |
700 | 0 | |a Gerhard Walzl |e verfasserin |4 aut | |
700 | 0 | |a Ashley Jacobs |e verfasserin |4 aut | |
700 | 0 | |a Robert J. Wilkinson |e verfasserin |4 aut | |
700 | 0 | |a Galit Alter |e verfasserin |4 aut | |
700 | 0 | |a Erwin Schurr |e verfasserin |4 aut | |
700 | 0 | |a Eileen G. Hoal |e verfasserin |4 aut | |
700 | 0 | |a Marlo Möller |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t EBioMedicine |d Elsevier, 2015 |g 61(2020), Seite 103053- |w (DE-627)DOAJ000039055 |x 23523964 |7 nnns |
773 | 1 | 8 | |g volume:61 |g year:2020 |g pages:103053- |
856 | 4 | 0 | |u https://doi.org/10.1016/j.ebiom.2020.103053 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/778da5d84cb64b9698dfc80977800634 |z kostenfrei |
856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2352396420304291 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2352-3964 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 61 |j 2020 |h 103053- |